07:00 , Jul 30, 2007 |  BC Week In Review  |  Company News

Advanced Magnetics hematology, diagnostic news

The company changed its name to AMAG Pharmaceuticals Inc. Advanced Magnetics Inc. (AMAG), Cambridge, Mass.   Business: Hematology, Diagnostic   ...
07:00 , Jul 30, 2007 |  BC Week In Review  |  Clinical News

Ferumoxytol: Preliminary Phase III data

In the open-label, U.S. Phase III 62745-5 trial in 230 patients, IV ferumoxytol met the primary endpoint of a significant improvement in baseline hemoglobin levels after 35 days compared with oral iron. Patients receiving 2-510...
07:00 , May 28, 2007 |  BioCentury  |  Finance

Adding up Addex

Buysiders were clearly split on the pricing of the Addex IPO on the SWX Swiss Exchange last week. Despite being more than four times over-subscribed, the stock - which priced last Monday at CHF73 a...
00:46 , May 24, 2007 |  BC Extra  |  Financial News

Advanced Magnetics raises $162.9 million

AMAG raised $162.9 million through the sale of 2.5 million shares at $65.14 in a bumped-up follow-on underwritten by Morgan Stanley; Bear Stearns; Deutsche Bank; Jefferies; and ThinkEquity. AMAG proposed to sell 2 million shares...
01:16 , May 17, 2007 |  BC Extra  |  Financial News

Advanced Magnetics proposes follow-on

AMAG proposed to sell 2 million shares in a follow-on underwritten by Morgan Stanley; Bear Stearns; Deutsche Bank; Jefferies; and ThinkEquity. If sold at AMAG's close of $64.97 on Wednesday, the company would raise $130...
07:00 , May 7, 2007 |  BioCentury  |  Finance

Ebb & Flow

Five executives at MedImmune (MEDI) will be receiving more than $280 million when the $15.6 billion acquisition by AstraZeneca (LSE:AZN; AZN) closes. By comparison, the biotech sector raised a total of $566 million last week,...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Clinical News

Ferumoxytol: Phase III data

In a double-blind, U.S. Phase III trial in 750 patients, adverse events with IV ferumoxytol were similar to those with placebo. Treatment-related adverse events occurred in 5.2% of ferumoxytol-treated patients and 4.2% of placebo-treated patients,...
07:00 , Apr 16, 2007 |  BC Week In Review  |  Clinical News

Ferumoxytol: Phase III data

In an open-label, U.S. Phase III trial in 303 non-dialysis dependent CKD patients, IV ferumoxytol met the primary endpoint of a better mean change in hemoglobin from baseline to day 35 than oral iron. At...
07:00 , Apr 16, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 4/13 cls Acadia (ACAD) JMP Securities Charles Duncan Price target Market outperform -1% $15.47 Duncan raised his target to $21 from $18. He said...
07:00 , Apr 9, 2007 |  BC Week In Review  |  Company News

Advanced Magnetics management update

Advanced Magnetics Inc. (AMAG), Cambridge, Mass.   Business: Hematology, Diagnostic   Hired: David Arkowitz as CFO and CBO, formerly CFO and treasurer of Idenix Pharmaceuticals Inc.   ...